Syndax Announces Participation in June Investor Conferences

Rhea-AI Summary

Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on innovative cancer therapies, has announced its participation in two major upcoming investor conferences in June 2025. CEO Michael A. Metzger and the management team will engage in fireside chats at the Jefferies Global Healthcare Conference on June 5 at 1:25 p.m. ET and the Goldman Sachs 46th Annual Global Healthcare Conference on June 11 at 2:00 p.m. ET. Both presentations will be available via live webcast on the company's website investor section, with replays accessible for a limited time.

News Market Reaction

+4.94%

1 alert

+4.94% News Effect

On the day this news was published, SNDX gained 4.94%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

• Jefferies Global Healthcare Conference with a fireside chat on Thursday, June 5, 2025, at 1:25 p.m. ET.
• Goldman Sachs 46^th Annual Global Healthcare Conference with a fireside chat on Wednesday, June 11, 2025, at 2:00 p.m. ET.

A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

FAQ

When is Syndax Pharmaceuticals (SNDX) presenting at the Jefferies Global Healthcare Conference 2025?

Syndax Pharmaceuticals will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 1:25 p.m. ET.

What time is SNDX's presentation at the Goldman Sachs Healthcare Conference 2025?

Syndax will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025, at 2:00 p.m. ET.

Who will represent Syndax Pharmaceuticals at the June 2025 investor conferences?

CEO Michael A. Metzger and members of the Syndax management team will represent the company at the conferences.

Where can investors watch Syndax's (SNDX) June 2025 conference presentations?

The presentations will be available via live webcast in the Investor section of Syndax's website at www.syndax.com, with replays available for a limited time.